Pimavanserin
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Pimavanserin
Description:
Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.Product Name Alternative:
ACP-103UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
5-HT ReceptorType:
Reference compoundRelated Pathways:
GPCR/G Protein; Neuronal SignalingApplications:
Neuroscience-NeuromodulationField of Research:
Neurological DiseaseAssay Protocol:
https://www.medchemexpress.com/pimavanserin.htmlPurity:
99.86Solubility:
DMSO : 50 mg/mL (ultrasonic)Smiles:
CC(C)COC1=CC=C(CNC(N(CC2=CC=C(F)C=C2)C3CCN(C)CC3)=O)C=C1Molecular Formula:
C25H34FN3O2Molecular Weight:
427.55Precautions:
H302, H315, H319, H335References & Citations:
[1]Vanover KE, et al. Pharmacological and behavioral profile of N- (4-fluorophenylmethyl) -N- (1-methylpiperidin-4-yl) -N'- (4- (2-methylpropyloxy) phenylmethyl) carbamide (2R,3R) -dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine (2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317 (2) :910-8.|[2]Vanover KE, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav. 2008 Oct;90 (4) :540-4.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
LaunchedIsoform:
5-HT2 Receptor; α-1 microglobulinCitation 01:
ACS Chem Neurosci. 2019 Nov 20;10 (11) :4476-4491. |bioRxiv. 2020 Feb.|Department Neuroscience. Virginia Commonwealth University. 2016 Oct.|Int J Clin Exp Med. 2019;12 (8) :10342-10349|Int J Neuropsychopharmacol. 2021 Sep 21;24 (9) :749-757.|J Med Chem. 2023 Jul 13;66 (13) :9057-9075.|Patent. US20200352950A1.|Proc Natl Acad Sci U S A. 2020 Oct 20;117 (42) :26438-26447.|Sci Rep. 2024 Jan 16;14 (1) :1396.|bioRxiv. 2023 Jul 31:2023.07.29.551106.|Food Chem Toxicol. 2023 Jun:176:113800.|Nat Commun. 2023 Dec 15;14 (1) :8221.CAS Number:
[706779-91-1]
